{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-304559","form_type":"8-K","ticker":"KURA","cik":"0001422143","company_name":"Kura Oncology, Inc.","filed_at":"2025-12-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.374384+00:00","generated_at":"2026-05-16T15:40:05.756591+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Kura Oncology completes first U.S. commercial sale of KOMZIFTI, triggering $135M milestone payment from Kyowa Kirin","bullets":["First commercial sale of KOMZIFTI (ziftomenib) completed on December 2, 2025.","Milestone triggers $135M payment from Kyowa Kirin, expected before year-end 2025.","KOMZIFTI received FDA approval on November 13, 2025.","Payment is under the existing collaboration and license agreement with Kyowa Kirin."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-304559","json":"https://secwatch.observer/filing/0001193125-25-304559.json","markdown":"https://secwatch.observer/filing/0001193125-25-304559.md","text":"https://secwatch.observer/filing/0001193125-25-304559.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422143/000119312525304559/0001193125-25-304559-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422143/000119312525304559/d75668d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T15:40:05.756591+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}